StreetInsider.com News Articles

Form ARS PFIZER INC For: Dec 31

Thu, 12 Mar 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260312/26150580.html

Form ARS PFIZER INC For: Dec 31

Thu, 12 Mar 2026 09:20:00 -0400

si-local-file:///var/storage/secattach/20260312/26150580.html

Form DEFA14A PFIZER INC

Thu, 12 Mar 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260312/26150520.html

Form DEFA14A PFIZER INC

Thu, 12 Mar 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260312/26150520.html

Form DEF 14A PFIZER INC For: Apr 23

Thu, 12 Mar 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260312/26150484.html

Form DEF 14A PFIZER INC For: Apr 23

Thu, 12 Mar 2026 09:07:00 -0400

si-local-file:///var/storage/secattach/20260312/26150484.html

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

March 11 (Reuters) - A key ‌U.S. federal vaccine advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.

Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

US vaccine advisers drop plan to question mRNA COVID shots, WaPo reports

Wed, 11 Mar 2026 06:32:30 -0400

BMO Capital Reiterates Outperform Rating on Pfizer (PFE) following Ph2 data

Mon, 09 Mar 2026 11:51:06 -0400

BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $30.00 price target on Pfizer (NYSE: PFE)

The analyst commented, "Ph 2 data for Pfizer's tri-specific antibody tilrekimig (IL-4/IL-13/TSLP) highlights an interesting early efficacy. The once-monthly investigational inhibitor demonstrated a placebo-adjusted high of 51.9% (middle dose) patients achieving EASI-75 at 16 weeks. This compares to a high of 36% at 16 weeks for Regeneron's Dupixent (IL-4/IL-13) in the Ph 3 SOLO 1 twice-monthly arm. While efficacy appears encouraging, we need to see detailed data before we can fully assess tilrekimig's therapeutic profile... Today's data highlights a potentially exciting catalyst path

FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'

Mon, 09 Mar 2026 10:53:22 -0400

FDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable.

The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs. In new draft guidance issued today, the agency recommended streamlining unnecessary clinical pharmacokinetic (PK) testing when scientifically justified. This change could save biosimilar developers up to 50% of their PK study costs, or approximately $20 million, and help lower drug costs.